文献速递骨软组织肉瘤与黑色素瘤

抑酸药与维莫非尼剂量对BRAFV600突变转移性黑色素瘤生存的影响

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.
PubMed 文献 · Eur J Cancer · 2019-06-04

该回顾性汇总分析纳入BRIM-2、BRIM-3、BRIM-7和coBRIM研究中的920例BRAFV600突变阳性不可切除或转移性黑色素瘤患者,评估抑酸药(ARA)联用与维莫非尼剂量对疗效的影响。结果显示,无论维莫非尼单药还是联合考比替尼,按剂量和ARA使用分组的生存结局与客观缓解率均无显著差异,稳态血药浓度也总体相似。提示ARA可与维莫非尼(单用或联合考比替尼)联用而不影响疗效。

要点

  • 汇总4项研究920例患者,按维莫非尼剂量和ARA使用分组,生存结局无显著差异。
  • 维莫非尼单药或联合考比替尼时,ARA联用未显著改变客观缓解率。
  • 389例稳态浓度分析显示,各剂量亚组浓度总体相似,与ARA使用无关。

核心结论

  • 回顾性汇总分析提示,抑酸药可与维莫非尼单用或联合考比替尼联用,而不损害维莫非尼的疗效。

研究设计与样本

  • 回顾性汇总分析,数据来自BRIM-2、BRIM-3、BRIM-7和coBRIM研究,疗效分析纳入920例BRAFV600突变阳性不可切除或转移性黑色素瘤患者。

主要发现

  • 在维莫非尼队列和考比替尼联合维莫非尼队列中,按维莫非尼剂量(全量 vs 减量)和ARA使用(是 vs 否)分组的生存结局均无显著差异,无论是否校正已知预后协变量。
  • 两个治疗队列中各亚组的客观缓解率也相似。
  • 389例患者(维莫非尼队列193例,联合队列196例)的稳态维莫非尼浓度在各剂量亚组间总体相似,与ARA使用无关。

临床怎么用

  • 对于需要抑酸治疗的BRAFV600突变转移性黑色素瘤患者,可考虑在维莫非尼单用或联合考比替尼治疗期间联用ARA,无需因疗效担忧而避免。

局限性

  • 为回顾性汇总分析,非前瞻性随机对照设计,可能存在未控制的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a retrospective analysis to evaluate the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of vemurafenib in patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. METHODS: Data were pooled for patients treated with vemurafenib or cobimetinib plus vemurafenib in the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies. The primary end-points were progression-free survival and overall survival across patient subgroups defined by vemurafenib dose (full vs reduced) and concomitant ARA use (yes vs no). Objective response rate (ORR) was also analysed. Steady-state vemurafenib concentrations were evaluated according to vemurafenib dosing and concomitant ARA use across treatment cohorts in a subset of patients from BRIM-7 and coBRIM with available concentration data. RESULTS: Efficacy analyses included 920 patients: 641 in the vemurafenib cohort and 279 in the cobimetinib plus vemurafenib cohort. Overall, no significant differences in survival outcomes were observed across subgroups according to vemurafenib dose and ARA use, with or without adjustment for known prognostic covariates, in both treatment cohorts. ORR was also similar across subgroups in both treatment cohorts. Steady-state vemurafenib concentrations were analysed in 389 patients (193 in the vemurafenib cohort and 196 in the cobimetinib plus vemurafenib cohort) and were generally similar across vemurafenib dose subgroups, regardless of ARA use in both treatment cohorts. CONCLUSIONS: Results of this retrospective pooled analysis suggest that ARAs can be used concomitantly with vemurafenib, alone or in combination with cobimetinib, without compromising the efficacy of vemurafenib.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lewis K, Hauschild A, Larkin J, et al. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. Eur J Cancer. 2019. PMID: 31173962. doi:10.1016/j.ejca.2019.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。